<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003163</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065959</org_study_id>
    <secondary_id>MCW-96110</secondary_id>
    <secondary_id>MCW-HRRC-29196</secondary_id>
    <secondary_id>NCI-V97-1368</secondary_id>
    <nct_id>NCT00003163</nct_id>
  </id_info>
  <brief_title>Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers</brief_title>
  <official_title>Myeloblative Therapy With Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma and B-Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Peripheral stem cell transplantation may allow doctors to give higher doses of&#xD;
      chemotherapy drugs and kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation in&#xD;
      treating patients who have multiple myeloma or other B-cell cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and efficacy of myeloablative therapy with autologous hematopoietic&#xD;
           stem cell transplantation in patients with multiple myeloma and other B-cell&#xD;
           malignancies.&#xD;
&#xD;
        -  Determine the efficacy and pretransplantation prognostic factors associated with&#xD;
           myeloablative therapy in these patients.&#xD;
&#xD;
        -  Determine engraftment kinetics of granulocytes and platelets, as well as blood product&#xD;
           transfusion requirements following hematopoietic stem cell transplantation.&#xD;
&#xD;
      OUTLINE: Patients must have hematopoietic stem cell procurement completed prior to&#xD;
      myeloablative therapy. Patients receive high dose chemotherapy with autologous hematopoietic&#xD;
      stem cell transplantation and supportive care. Melphalan is administered in one dose on day&#xD;
      -1 at least 12 hours before stem cell infusion. Peripheral blood stem cells and/or bone&#xD;
      marrow is reinfused on day 0. Filgrastim (G-CSF) or sargramostim (GM-CSF) is administered&#xD;
      beginning on day 1 posttransplantation and continuing until blood counts recover.&#xD;
&#xD;
      Patients who are not candidates for tandem transplant may receive melphalan plus total body&#xD;
      irradiation (TBI). Melphalan is administered IV on day -4. Total body irradiation is&#xD;
      administered three times a day on days -3 and -2 and twice on day -1. At least 4 hours must&#xD;
      elapse between each treatment. Hematopoietic stem cells are reinfused on day -1 upon&#xD;
      completion of TBI or on day 0.&#xD;
&#xD;
      If patient is ineligible for melphalan plus TBI, the alternative single high dose regimen of&#xD;
      melphalan plus cyclophosphamide is administered. Melphalan, for these patients, is given in&#xD;
      two equal doses on day -4 followed by two consecutive days of cyclophosphamide on days -3 and&#xD;
      -2. Hematopoietic stem cells are reinfused on day 0.&#xD;
&#xD;
      A second transplant may be considered, preferably between 3 and 6 months after the first&#xD;
      transplant. The preferred regimen for the second transplant is melphalan alone or melphalan&#xD;
      plus TBI as described above. The alternative regimens for the second dose therapy are&#xD;
      melphalan alone or melphalan plus cyclophosphamide. For patients receiving melphalan alone,&#xD;
      melphalan is administered in one dose on day -1 at least 12 hours before stem cell infusion.&#xD;
      Hematopoietic stem cells are reinfused on day 0 for both alternative regimens.&#xD;
&#xD;
      Patients are followed for response from treatment for a minimum of 4 weeks and then&#xD;
      periodically for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A minimum of 10 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 1997</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed multiple myeloma or other B-cell malignancy including&#xD;
             non-Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, or amyloidosis&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma with T-cell immunophenotypes included&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 2,000/mm^3 (unless due to disease)&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3 (unless due to disease)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF at least 40%&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO or FVC and FEV1 at least 50% of predicted unless due to restriction from volume&#xD;
             loss secondary to disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No overt infection or unexplained fever requiring broad spectrum antibiotics&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 2 weeks since prior biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 2 weeks since other prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 2 weeks since prior endocrine therapy&#xD;
&#xD;
          -  Concurrent steroids allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David H. Vesole, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2002</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 17, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2003</study_first_posted>
  <last_update_submitted>January 3, 2014</last_update_submitted>
  <last_update_submitted_qc>January 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2014</last_update_posted>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>Waldenstr√∂m macroglobulinemia</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>primary systemic amyloidosis</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

